Alexandra Poole (Lead Cancer Nurse, Oxford University
Hospitals NHS Foundation Trust) and Nicky Swadling (Cancer Manager, Oxford
University Hospitals NHS Foundation Trust) have been invited to present a
report on Cancer Services in Oxfordshire. The Committee is particularly
interested in waiting times as well as treatments being offered for cancer
patients.
The Committee is invited to consider the report, raise any
questions and AGREE any recommendations arising it may wish to make.
Minutes:
Oxford University Hospitals NHS Foundation Trust were
invited to present a report on Cancer Services in Oxfordshire. The Committee
was particularly interested in waiting times as well as treatments being
offered for cancer patients.
Felicity Taylor Drewe (Chief Operating Officer, Oxford
University Hospitals NHS Foundation Trust), Andy Peniket (Clinical Director for
Oncology & Haematology OUH NHS FT), Matthew Tait (BOB ICB Chief Delivery
Officer), and Ansaf Azhar (Director of Public Health), attended to answer
questions from the Committee in relation to the cancer wait times and treatment
report.
The Chief Operating Officer at Oxford University Hospitals
(OUH), discussed the Annual Cancer Survey feedback, noting improvements and
performance against other trusts. The report included Cancer Outcomes and
Services Dataset (COSD) data on treatment access and clinical outcomes, with an
emphasis on personalised care.
Members inquired about the methods used by staff to provide
patients with relevant information on available support and treatments. The
Chief Operating Officer at OUH and Clinical Director for Oncology and
Haematology described the various approaches utilised to inform patients about
available support and treatments. These methods included distributing
informational leaflets, offering direct communication during appointments, and
employing marketing strategies to promote NHS hearing tests and treatments. Additionally,
there was a strong emphasis on patient follow-ups to ensure the effectiveness
of treatments and to promptly address any issues. This comprehensive approach
aimed to enhance patient awareness and engagement with the services provided.
The Committee inquired about the support available for
patients who do not speak English, citing a Healthwatch report that highlighted
an instance where a non-English speaking patient was unaware of their diagnosis
due to communication barriers. Members asked about the challenges and
monitoring of support for these individuals. The OUH Chief Operating Officer
acknowledged that providing support for non-English speaking patients was a
significant concern. The Committee therefore reiterated the need to address the
challenges and monitor the support mechanisms for such patients.
Members inquired about the commitment to the well-being of
patients and their families, particularly concerning mental health, and whether
this responsibility rested with the hospital or was referred back to the local
GP. The Chief Operating Officer and Clinical Director explained that the
responsibility for the well-being of both patients and their families,
especially regarding mental health, was recognised as significant.
The Officers clarified that this responsibility was shared
between the hospital and the local GP, depending on the specific circumstances
and needs of the patient. The hospital provided immediate and specialised
mental health support, while ongoing care and follow-up were typically managed
by the local GP. This collaborative approach ensured comprehensive and
continuous care for the patient's mental health and overall well-being.
Members inquired about OUH's performance in the National
Cancer Patient Survey, particularly concerning the KPI that measures patients
definitively receiving the appropriate level of support from their GP practice
during treatment, which was at 50%. They also asked about patient involvement
in discussing their treatment and ways to enhance the support experience from
GPs.
It was acknowledged, by Officers, that the 50% KPI indicates
an area needing improvement. Efforts are being made to ensure patients are more
actively involved in discussions about their treatment. To improve the
experience of support from GPs, it was suggested that better communication and
coordination between the hospital and GP practices were essential. This would
help ensure patients receive consistent and comprehensive support throughout
their treatment journey.
Members inquired about the increase in cancer referrals
across Oxfordshire, seeking to determine whether this rise was associated with
specific towns, districts, PCNs, or GP practices, and if there were any
demographic factors influencing this trend. The Chief Operating Officer and
Clinical Director clarified that the rise in cancer referrals was not linked to
specific locations or PCNs. Instead, it was observed as a general trend
throughout the region, with no particular demographic factors identified as contributing
to the increase. The rise in referrals appeared to be part of a broader pattern
rather than being connected to specific localities or demographic groups.
Members inquired about the challenges faced by the workforce
in cancer services and discussed the potential impact and necessary support if
the assisted dying Bill, which was under review in Parliament, were legislated.
The Clinical Director emphasised that the workforce in cancer services was
experiencing significant difficulties, including high demand and staffing
shortages. These issues were adversely affecting the ability to deliver timely
and comprehensive care to patients.
Concerning the possible implications of the assisted dying
Bill, it was recognised that substantial support and resources would be
required for effective implementation if it became law. This included training
for healthcare professionals, the establishment of clear guidelines, and robust
support systems to ensure the new legislation could be integrated into existing
cancer care services without compromising the quality of care.
Members enquired about the role of co-production in the development
of cancer services and requested an update on stakeholder involvement in this
process. Officers clarified that co-production had played a significant role in
the development of cancer services. Key stakeholders, which included patients,
healthcare professionals, and community organisations, were actively engaged in
the process. This collaborative approach ensured that the services were
tailored to meet the needs of those affected by cancer. Regular engagement
sessions, feedback mechanisms, and working groups were utilised to gather input
and integrate it into service planning and improvement. This approach aimed to
create more patient-centred and effective cancer care services.
Cllr Leverton left the meeting at this stage.
Members inquired about the modifications to the national
cancer standards of measurement, specifically addressing the rationale behind
these changes, the implications of eliminating the two-week waiting period for
patients, and the performance of OUH in relation to these new standards. The
Clinical Director and Chief Operating Officer elucidated that the revisions to
the national cancer standards were implemented to streamline procedures and
enhance patient outcomes. The elimination of the two-week waiting period was
designed to minimise delays and ensure timely and appropriate care for
patients.
The expected impact on patients was positive, with an
emphasis on quicker diagnosis and treatment. OUH was performing commendably
against these newly established standards, meeting the targets and ensuring
that patients received necessary care within the updated timeframes.
Members inquired about the significance of outcome data in
cancer treatment, the national comparison of OUH's outcomes, and the gap in
treatments to achieve optimal results. The Chief Operating Officer and Clinical
Director underscored the vital role of outcome data in cancer treatment, as it
provided valuable insights into the effectiveness of therapies and highlights
areas needing enhancement. OUH's performance favourably compared to national
outcomes, excelling in several key areas.
Nonetheless, there remained a recognised treatment gap in
achieving the best outcomes, attributed to factors such as resource limitations
and the necessity for ongoing improvements in treatment protocols. Initiatives
were underway to address these gaps and improve the overall quality of cancer
care.
The Committee AGREED to recommendations under the
following headings:
Supporting documents: